The Argenta website uses cookies to store information on your computer, to improve our website. One of the cookies we use is essential for parts of the site to operate and has already been set. You may delete and block all cookies from this site, but parts of the site will not work. To find out more about the cookies we use and how to delete them, see our privacy notice.

I accept cookies from this site
 

In this section...

De-risking Preclinical Molecules

Argenta has comprehensive capability to support the early assessment and selection of robust pre-clinical molecules, including biomarkers, PK/PD, pharmaceutics, safety and process chemistry provisions. Drug discovery organisations can access all of our technologies through our integrated service and take advantage of our expertise and advice, along with a battery of capabilities. Use our integrated service on your internal drug discovery projects to help identify your most robust molecules and advance these to pre-clinical candidates faster.

  • PK/PD
    Bioanalysis, PK/PD Analysis & Modelling, Metabolite Identification and PK profiling
  • Biomarker Identification
    Transferring research success into clinical success
  • Early Safety Assessment
  • Pharmaceutics
    Analytics & Structural Analysis, Physical Property Measurement, Solubility & Dissolution, Polymorphism Screening, Salt Screening and API/IMP Stability Screening
  • Process & Scale-up Chemistry
    Translating research routes into scaleable processes

For more information on our pre-clinical candidate de-risking capabilities please contact us.


Print to HTML

Innovation. Expertise. Delivered